Effect of pristimerin on adriamycin resistance of osteosarcoma cells by regulating Hippo/YAP signal pathway

LI Hao; RONG Shuai; LIU Lian-tao

doi:10.11659/jjssx.06E023007

您当前的位置：

首页 >

文章列表页 >

Effect of pristimerin on adriamycin resistance of osteosarcoma cells by regulating Hippo/YAP signal pathway

Basic Research | 更新时间：2024-09-29

- Effect of pristimerin on adriamycin resistance of osteosarcoma cells by regulating Hippo/YAP signal pathway
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 9, Pages: 796-799(2024)
- 作者机构：
  
  石家庄市第三医院小儿骨科，河北石家庄 050000
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.06E023007
  CLC： R73-37
- Published：25 September 2024，
  
  Received：01 June 2023，
- 稿件说明：
移动端阅览
李浩,戎帅,刘连涛.扁蒴藤素调节Hippo/YAP信号通路对骨肉瘤细胞阿霉素耐药性的影响[J].局解手术学杂志,2024,33(09):796-799.

LI Hao,RONG Shuai,LIU Lian-tao.Effect of pristimerin on adriamycin resistance of osteosarcoma cells by regulating Hippo/YAP signal pathway[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(09):796-799.
李浩,戎帅,刘连涛.扁蒴藤素调节Hippo/YAP信号通路对骨肉瘤细胞阿霉素耐药性的影响[J].局解手术学杂志,2024,33(09):796-799. DOI： 10.11659/jjssx.06E023007.

LI Hao,RONG Shuai,LIU Lian-tao.Effect of pristimerin on adriamycin resistance of osteosarcoma cells by regulating Hippo/YAP signal pathway[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(09):796-799. DOI： 10.11659/jjssx.06E023007.

摘要

目的

探讨扁蒴藤素（PM）对骨肉瘤细胞阿霉素（ADM）耐药性的影响及其作用机制。

方法

采用ADM浓度梯度递增长期培养法在体外建立ADM耐药细胞MG-63/ADR，CCK-8检测不同浓度ADM对骨肉瘤细胞MG-63和MG-63/ADR细胞活力的影响，验证ADM耐药性；随后将MG-63/ADR细胞随机分为MG-63/ADR组（正常培养）、PM低剂量组（加入0.5 μmol/L PM）、PM中剂量组（加入1.0 μmol/L PM）、PM高剂量组（加入2.0 μmol/L PM），CCK-8检测不同浓度ADM处理下各组细胞活力；平板克隆形成实验检测各组细胞对ADM的敏感性；显微镜下观察细胞形态；流式细胞术检测细胞凋亡水平；Western blot检测磷酸化哺乳动物STE20样蛋白激酶1（p-MST1）、MST1、磷酸化大肿瘤抑制因子1（p-LATS1）、LATS1、磷酸化Yes相关蛋白（p-YAP）、YAP蛋白表达。

结果

25、125、625、3 125、15 625 ng/mL ADM干预下，MG-63/ADR细胞活力较MG-63细胞显著升高（

0.05），说明ADM耐药细胞模型建立成功。与MG-63/ADR组相比，PM低、中、高剂量组细胞数量减少且细胞逐渐皱缩、间距变大，细胞活力、细胞克隆形成率以及p-YAP/YAP水平下降（

0.05），细胞凋亡率和p-MST1/MST1、p-LATS1/LATS1水平显著提高（

0.05）。

结论

PM对骨肉瘤细胞ADM耐药性具有抑制作用，其可能与激活Hippo通路、下调YAP信号有关。

Abstract

Objective

To investigate the effect of pristimerin （PM） on adriamycin （ADM） resistance in osteosarcoma cells and its mechanism.

Methods

The ADM resistant cells MG-63/ADR was established in vitro by using the ADM increasing concentration gradient long-term culture method， CCK-8 was used to detect the effects of different concentrations of ADM on the viability of osteosarcoma cells MG-63 and MG-63/ADR cells to verify the drug resistance of ADM； subsequently， MG-63/ADR cells were randomly divided into the MG-63/ADR group （normal culture）， low-dose PM group （adding 0.5 μmol/L PM）， middle-dose PM group （adding 1.0 μmol/L PM） and high-dose PM group （adding 2.0 μmol/L PM）. The cell viability of each group under different concentrations of ADM treatment was detected by CCK-8； the sensitivity of cells to ADM in each group was detected by plate clone formation assay； the cell morphology of each group was observed under microscope； the cell apoptosis level was detected by flow cytometry； Western blot was used to detect the expression of phosphorylated mammalian STE20-like protein kinase 1 （p-MST1）， MST1， phosphorylated large tumor suppressor 1 （p-LATS1）， LATS1， phosphorylated Yes associated protein （p-YAP） and YAP proteins.

Results

With the intervention of 25， 125， 625， 3 125 and 15 625 ng/mL ADM， the activity of MG-63/ADR cells was significantly higher than that of MG-63 cells （

0.05）， which indicated that the ADM resistant cell model was successfully established. Compared with the MG-63/ADR group， the number of cells in the low， middle and high-dose PM groups decreased， and the cells gradually shrank， the spacing between cells became larger， and the cell viability， cell clonal formation rate and p-YAP/YAP level decreased （

0.05）， the apoptosis rate and the levels of p-MST1/MST1 and p-LATS1/LATS1 significantly increased （

0.05）.

Conclusion

The inhibitory effect of PM on ADM resistance in osteosarcoma cells may be related to the activation of Hippo pathway and the downregulation of YAP signal.

关键词

扁蒴藤素骨肉瘤Hippo/Yes相关蛋白阿霉素耐药性

Keywords

pristimerinosteosarcomaHippo/Yes associated proteinadriamycin resistance

references

Belayneh R，Fourman MS，Bhogal S，et al.Update on osteosarcoma［J］.Curr Oncol Rep，2021，23（6）：71.doi：10.1007/s11912-021-01053-7http://dx.doi.org/10.1007/s11912-021-01053-7.

Eaton BR，Schwarz R，Vatner R，et al.Osteosarcoma［J］.Pediatr Blood Cancer，2021，68（Suppl 2）：e28352.doi：10.1002/pbc.28352http://dx.doi.org/10.1002/pbc.28352.

周程成，陈秀生，周智辉.铁死亡逆转肿瘤细胞化疗药物耐药性的研究进展［J］.中华实用诊断与治疗杂志，2019，33（11）：1128-1130.doi：10.13507/j.issn.1674-3474.2019.11.023http://dx.doi.org/10.13507/j.issn.1674-3474.2019.11.023.

白殊同，佟丽，王琴，等.过山枫活性成分扁蒴藤素药理作用研究进展［J］.中国药理学通报，2019，35（3）：318-321.doi：10.3969/j.issn.1001-1978.2019.03.006http://dx.doi.org/10.3969/j.issn.1001-1978.2019.03.006.

Mori Y，Shirai T，Terauchi R，et al.Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo［J］.Onco Targets Ther，2017，10：5703-5710.doi：10.2147/OTT.S150071http://dx.doi.org/10.2147/OTT.S150071.

Xie G，Yu X，Liang H，et al.Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling［J］.Oncol Lett，2016，11（5）：3111-3116.doi：10.3892/ol.2016.4335http://dx.doi.org/10.3892/ol.2016.4335.

马小雨，戴泽宇，钟南哲，等.Hippo信号通路中YAP/TAZ在骨肉瘤中的研究进展［J］.实用骨科杂志，2022，28（8）：727-730.

张义，张擎柱，谷锐，等.lncRNA FOXC2-AS1逆转骨肉瘤细胞对阿霉素耐药性的影响［J］.临床肿瘤学杂志，2019，24（5）：385-390.doi：10.3969/j.issn.1009-0460.2019.05.001http://dx.doi.org/10.3969/j.issn.1009-0460.2019.05.001.

徐婷，程名，王叙德.扁蒴藤素对肝细胞癌细胞Hep3B增殖和凋亡的影响［J］.中国临床药理学杂志，2022，38（14）：1607-1611.doi：10.13699/j.cnki.1001-6821.2022.14.009http://dx.doi.org/10.13699/j.cnki.1001-6821.2022.14.009.

Cersosimo F，Lonardi S，Bernardini G，et al.Tumor-associated macrophages in osteosarcoma：from mechanisms to therapy［J］.Int J Mol Sci，2020，21（15）：5207.doi：10.3390/ijms21155207http://dx.doi.org/10.3390/ijms21155207.

郭卫，牛晓辉，肖建如，等.骨肉瘤临床循证诊疗指南［J］.中华骨与关节外科杂志，2018，11（4）：288-301.doi：10.3969/j.issn. 2095-9958.2018.04.005http://dx.doi.org/10.3969/j.issn.2095-9958.2018.04.005.

Lilienthal I，Herold N.Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma：a review of current and future strategies［J］.Int J Mol Sci，2020，21（18）：6885.doi：10.3390/ijms21186885http://dx.doi.org/10.3390/ijms21186885.

Morice S，Danieau G，Rédini F，et al.Hippo/YAP signaling pathway：a promising therapeutic target in bone paediatric cancers？［J］.Cancers （Basel），2020，12（3）：645.doi：10.3390/cancers12030645http://dx.doi.org/10.3390/cancers12030645.

Ma S，Meng Z，Chen R，et al.The Hippo pathway：biology and pathophysiology［J］.Annu Rev Biochem，2019，88：577-604.doi：10.1146/annurev-biochem-013118-111829http://dx.doi.org/10.1146/annurev-biochem-013118-111829.

Cobbaut M，Karagil S，Bruno L，et al.Dysfunctional mechanotransduction through the YAP/TAZ/Hippo pathway as a feature of chronic disease［J］.Cells，2020，9（1）：151.doi：10.3390/cells9010151http://dx.doi.org/10.3390/cells9010151.

Guo Y，Luo J，Zou H，et al.Context-dependent transcriptional regulations of YAP/TAZ in cancer［J］.Cancer Lett，2022，527：164-173.doi：10.1016/j.canlet.2021.12.019http://dx.doi.org/10.1016/j.canlet.2021.12.019.

Kovar H，Bierbaumer L，Radic-Sarikas B.The YAP/TAZ pathway in osteogenesis and bone sarcoma pathogenesis［J］.Cells，2020，9（4）：972.doi：10.3390/cells9040972http://dx.doi.org/10.3390/cells9040972.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Midazolam inhibits proliferation, migration and induces apoptosis of osteosarcoma cells

Effects of Wnt/β-catenin signaling pathway on hypoxia induced proliferation and invasion of osteosarcoma cell in vitro

Expression of PRR11 and its effect on proliferation of human osteosarcoma cells

Study on the mechanism of hypoxia-induced IL-11 secretion in osteosarcoma cell line U2OS

MicroRNA-10b promotes the proliferation and invasion of osteosarcoma cell lines by targeting twist gene

Related Author

JI Guo-li

ZHOU Quan-jun

JI Ying-long

REN Xiao-bao

ZHANG Jun

LI Ke

QIU Jin

XIAO Wei

Related Institution

Second Department of Anesthesiology， Weifang Hospital of Traditional Chinese Medicine

Department of Emergency,the First Hospital Affiliated to AMU (Third Military Medical University)

Department of Orthopedics，Tongchuan People’s Hospital

Department of Orthopedics,Chengdu Military General Hospital

Cancer Hospital Affiliated to Chongqing University,Chongqing Key Laboratory for Cancer Metastasis and Individualized Treatment Resrarch

⁰